CSF hypocretin-1 levels in schizophrenics and controls: Relationship to sleep architecture

Psychiatry Research

Volumn 110, Issue 1, 2002, Pages 1-7

  Nishino, Seiji ^a,c   Ripley, Beth ^a   Mignot, Emmanuel ^a   Benson, Kathleen L ^b   Zarcone, Vincent P ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c Stanford California and Cofounder   (United States)

Author keywords

Corticotropin releasing hormone; Orexin; Polysomnography; Radioimmunoassay

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; OREXIN A;

ADULT; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; LATENT PERIOD; MALE; MENTAL DISEASE; NEUROENDOCRINE DISEASE; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCHIZOPHRENIA; SLEEP; SLEEP DISORDER; SLEEP TIME; STATISTICAL SIGNIFICANCE;

ADULT; CARRIER PROTEINS; CHRONIC DISEASE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEUROPEPTIDES; PITUITARY-ADRENAL SYSTEM; POLYSOMNOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; SCHIZOPHRENIA; SLEEP STAGES; SYNAPTIC TRANSMISSION;

EID: 0037094044     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(02)00032-X     Document Type: Article

References (34)

1. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia
2. Evidence for the role of serotonin in the regulation of slow wave sleep in schizophrenia
3. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity
4. Stage 4 sleep in schizophrenia
5. Unusually high dream time in a hallucinating patient
6. A dopaminergic-cholinergic mechanism in production of psychotic symptoms
7. Orexinergic innervation of POMC-containing neurons in the rat arcuate nucleus
8. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: Response to amitriptyline treatment
9. Effects of orexins on the hypothalamic-pituitary-adrenal system
10. Sleep disturbance in acute schizophrenic patients
11. Centrally administered orexin/hypocretin activates HPA axis in rats
12. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system
13. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients
14. Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: Relationship to sleep architecture
15. Hypocretin (orexin) deficiency in human narcolepsy
16. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy
17. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains
18. Sleep disturbance in schizophrenia
19. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions
20. CSF corticotropin-releasing hormone in depressed patients and normal control subjects
21. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior
22. The dopamine hypothesis in schizophrenia: Focus on the dopamine receptor
23. Research Diagnostic Criteria: Rationale and reliability
24. All night sleep studies of acute schizophrenics
25. Cholinergic hyperactivity and negative schizophrenia symptoms
26. Relationship between DST non-supression and shortened REM latency in schizophrenia
27. Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement and outcome
28. Sleep stage deficits in chronic schizophrenia
29. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin
30. 2 dopamine receptors in drug-naive schizophrenics
31. Sleep and schizophrenia
32. Abnormal rapid eye movement latencies in schizophrenia